← Leaderboards
Wendy A Spencer
3p Biotechnologies, Inc.
$1,141,179
Attributed
$2,282,358
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2012–22$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$2,282,358 · 3
By mechanism
R44$1,719,680 · 1
R43$298,171 · 1
R41$264,507 · 1
Top collaborators
- Ramesh C Gupta5 shared
Most similar at 3p Biotechnologies, Inc.
Same institution · by research overlap
- Rena Margaret Wallen$253,226
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoToxic EffectIn VitroIntravenousTissuesDrug Delivery SystemsInnovationExosomeImmune ResponseDoseExhibitsFormulationDiagnosisBaseDrug FormulationsClinical TrialsBiological AvailabilityColostrumCattleCell Culture TechniquesCancer CellBloodCancer TherapyCells
Grant awards (5)
Engineered Exosomes for Targeted Delivery of the CRISPR/Cas9 Genome-editor$264,507
R41 · FY2022 · OD
Exosomal Drug Delivery$1,000,000
R44 · FY2018 · CA · contact PI
Exosomal Drug Delivery$719,680
R44 · FY2017 · CA · contact PI
Sustained, target delivery for treatment of cervical pathologies$45,061
R43 · FY2013 · CA · contact PI
Sustained, target delivery for treatment of cervical pathologies$253,110
R43 · FY2012 · CA · contact PI